Am I the only one concetrating on NNZ2591 and seeing DAYBUE as just the "reasonably successful" stepping stone to NNZ2591 production? A treatment for several neurological disorders as yet not restricted to just the 3 we are currently trialing..... Angelmans results will be as good if not better than the last two, of that I am almost certain of.
I also see the slightly weak DAYBUE results as not being a disaster for NEW and in no way does it restrict the go-ahead plas for NNZ2591.
Acadia should be testing and promoting NNZ2591 for Rett Syndrome as they have the rights to do that. Instead they want to get some more blood from the trofinetide stone first.
Ann: Trading Halt, page-32
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.80 |
Change
-0.830(5.31%) |
Mkt cap ! $1.924B | |||
| Open | High | Low | Value | Volume |
| $15.65 | $15.72 | $14.76 | $11.61M | 772.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 9544 | $14.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.84 | 734 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |